Emerging Dementia Therapies - What GPs need to know - Primary Care Masterclass Podcast

Emerging Dementia Therapies Prof James Burrell

This podcast focuses on the rapidly evolving field of emerging dementia therapies, particularly those targeting Alzheimer's disease pathology, which has gained significant attention in the past year in Australia. The lecturer outlines the current landscape of therapies, providing a comprehensive background on their development and intended use. Participants are informed about who may be eligible for these therapies and the underpinning science that elucidates the role of amyloid pathology in Alzheimer's disease.

The discussion begins by explaining that Alzheimer's disease is characterized by amyloid deposition, a pathological change that can precede clinical symptoms by several decades. Clinical insights on the progression of the disease indicate that while amyloid accumulation occurs silently, once a threshold is reached, patients begin to exhibit cognitive symptoms. The aim of current therapies is to intervene at this early stage to delay, slow, or prevent the advancement of severe dementia. Insights into the progression highlight that while amyloid pathology is the primary target, tau protein accumulation also plays a crucial role in neuronal damage and cognitive decline.

As the lecture progresses, the focus shifts to specific anti-amyloid therapies that have received clinical approval. Denanimab emerges as the first approved therapy in Australia, following its international introduction. The historical context regarding the approval of aducanumab is discussed, touching upon the controversies surrounding its efficacy and market withdrawal. The speaker emphasizes the continued interest in effective treatments, particularly denanimab, which has demonstrated solid results in clearing amyloid from the brain as evidenced by amyloid PET scans.

Clinical trial data forms a substantial part of the conversation. The TRAIL-BLAZER study is highlighted for its rigorous methodology and the specific patient demographic it encompasses—those with mild cognitive impairment or mild dementia. Essential inclusion criteria such as confirmed Alzheimer's pathology through amyloid PET scans and careful screening for other potential brain abnormalities are detailed. The findings indicate that denanimab administration results in significant amyloid clearance, which correlates with a notable slowing of cognitive decline, especially in those with lower levels of tau deposition.

The risks associated with these treatments are also cautiously examined. The concept of amyloid-related imaging abnormalities (ARIA), broken down into ARIA-E and ARIA-H categories, is introduced. Regular monitoring via MRI scans is mandated to detect any adverse effects, even if initial episodes are often asymptomatic. While the statistics suggest a concerning rate of ARIA events, the lecturer reassures that the majority of these occurrences do not lead to significant clinical symptoms. Special attention is paid to the impact of APOE4 gene status on treatment eligibility and outcomes, further complicating the clinical landscape.

In discussing treatment logistics, the lecture elaborates on the necessary pre-treatment assessments and ongoing monitoring requirements. The treatment schedule for denanimab involves frequent infusions and MRI scans within the first year, setting a rigorous protocol to ensure patient safety and drug efficacy. Considering the financial implications, the speaker notes that these therapies are not currently subsidized by the PBS, presenting a barrier for many patients seeking treatment.

Concluding the lecture, the speaker underscores the transformative potential of early diagnosis and intervention in Alzheimer's disease through these disease-modifying therapies. While significant benefits are expected for patients with early-stage symptoms, the overarching goal remains the identification and treatment of asymptomatic individuals to prevent future cognitive decline. The discussion closes on an optimistic note, highlighting the ongoing advancements in research that may lead to even more effective treatment paradigms in the near future.

-------------------------------------------------------------------------------

Access thousands of premium conference podcasts and 'full video' podcasts including synchronised PowerPoint slides at https://www.armchairmedical.tv/podcasts

General Practitioners: Earn your full year's worth of CPD including Educational Activities, Reviewing Performance and Measuring Outcomes CPD Hours.

Discover more at https://www.armchairmedical.tv/podcasts

Press play. You’re at the conference.

In every episode of ArmchairMedical Conference Podcasts, we bring Australia’s leading medical conference education straight to your headphones.

No travel.

No full days away from clinic.

No disruption to your life.

Each episode features real conference lectures, captured live and carefully curated into short, practical, evidence-based podcasts designed for busy general practitioners.

Whether you’re commuting, exercising, or moving through the gaps of your day, this is conference-quality learning that fits real GP life.

If you value staying at the leading edge of medicine, but don’t have the time to attend every conference, this is the smart way to do it.

🎧 Press play. You’re at the conference.

About ArmchairMedical Conference Podcasts

ArmchairMedical Conference Podcasts transform Australia’s best medical conferences into on-demand audio education for GPs. Learn from leading clinicians and experts, anytime and anywhere, in a format designed to work with - not against - your day.

Enjoying the episode?

⭐ Rate this episode

➕ Follow the podcast

💬 Share it with a colleague who’d value conference learning without the time away

Disclaimer: Content is for health professionals and general educational purposes only. It is not medical advice or a substitute for independent clinical judgement. Always consult current guidelines, product information and local protocols. Views expressed are those of the presenters and not necessarily ArmchairMedical. ArmchairMedical accepts no responsibility or liability for any loss or harm resulting from reliance on the information provided.

Visit https://www.armchairmedical.tv/podcasts for more information.